Molecular data
| Molecular formula | C212H350N56O78S |
|---|---|
| Molecular weight | 4963.44 Da |
| Sequence length | 43 residues |
| Physical form | Lyophilized Powder |
| Available sizes | 10mg |
How it works
Cell Migration & Motility
TB-500 binds G-actin monomers, with actin polymerisation and cell migration toward injury sites measured in preclinical models. This is the mechanism most often characterised.
- Sequesters G-actin to regulate polymerization
- Cell migration to injury sites measured
- Cytoskeletal remodelling observed
Cardiac ILK Signalling
In cardiac research, TB-500 is studied for integrin-linked kinase (ILK) signalling and cardiac progenitor cell migration.
- Activates integrin-linked kinase (ILK)
- Cardiac progenitor cell migration measured
- Cardiac progenitor migration models
Inflammation Modulation
Lower pro-inflammatory cytokines and altered macrophage activity are measured, with the immune profile shifting from inflammatory to reparative-phase markers in preclinical wound models.
- Lower pro-inflammatory cytokines measured
- Modulates macrophage polarization
- Anti-fibrotic tissue remodelling observed
What the research shows
Wound Closure Models
Studied for dermal wound closure, scarring and organized collagen deposition in preclinical wound models.
Cardiac Models
Studied for cardiac cell migration via ILK activation in post-infarction models.
Corneal Models
Studied in corneal epithelial wound closure and inflammation in ocular surface models.
Soft Tissue Models
Studied in muscle, tendon and ligament models through actin-mediated cell migration and fibrotic scoring.
Specification
| Active Fragment | Thymosin Beta-4 (Tβ4) active region |
|---|---|
| Amino Acids | 43-amino acid peptide |
| Molecular Weight | 4,963 Da |
| Form | Lyophilized powder (10mg) |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
Frequently asked questions
What is TB-500?
TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (Tβ4), a 43-amino acid protein naturally found in all nucleated cells. Tβ4 is studied for its role in cell migration, differentiation and tissue remodelling through its interaction with the actin cytoskeleton.
How does TB-500 differ from Thymosin Beta-4?
TB-500 contains the active fragment of the full Thymosin Beta-4 protein. While Tβ4 is the complete 43-amino acid sequence, TB-500 focuses on the region responsible for actin binding and cell migration properties. Both share the same core mechanism of action.
What is TB-500's regulatory status?
TB-500 is not approved by the FDA or any regulatory agency for human use. It is a fragment of thymosin beta-4 supplied exclusively for in vitro laboratory research, and no safety profile in humans is established for the material sold here.
What are the primary research applications?
TB-500 is studied in preclinical models covering wound closure, cardiac tissue, corneal surface, muscle and tendon, and inflammatory signalling. Its primary mechanism — cell migration via actin regulation — is common to all of them.
How should TB-500 be stored?
Store lyophilized TB-500 at -20°C for long-term stability. Avoid repeated freeze-thaw cycles and protect from light.
Is TB-500 FDA approved?
No. TB-500 is not FDA approved for any indication. It is available exclusively for in vitro laboratory research. TB-500 has not received regulatory approval, and the material sold here is not the pharmaceutical formulation of thymosin beta-4.
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.